header logo image


Page 537«..1020..536537538539..550560..»

Precision Medicine and Diagnostics Expert Hakan Sakul, Ph.D., of Pfizer Joins the Progentec Board of Directors – BioSpace

June 6th, 2020 8:48 pm

OKLAHOMA CITY, June 3, 2020 /PRNewswire/ --Progentec, a leader in next-gen diagnostics and digital technologies for the management of autoimmune diseases, announced today that Hakan Sakul, Ph.D., Vice President and Head of Diagnostics at Pfizer, has joined the Progentec Board of Directors. Dr. Sakul has a distinguished track record in the development and commercialization of companion diagnostics, precision medicine, and pharmacogenomics. His wealth of experience and knowledge will support Progentec in its mission to improve health outcomes for people living with autoimmune diseases.

"Lupus is a difficult disease to diagnose and a lab-based testing is sorely needed to confirm its diagnosis," said Dr. Sakul. "I am delighted to join Progentec's Board in this important phase of the company's diagnostics development journey."

In addition to his R&D, clinical, and product expertise, Dr. Sakul has deep experience in regulatory policy. He is currently a member of California Gov. Newsom's Precision Medicine Advisory Council, and was previously an Advisory Board member for California Gov. Brown's Precision Medicine Advisory Committee. Dr. Sakul is also on the board of directors for the Personalized Medicine Coalition and serves on Luminex Corporation's Oncology Advisory Committee.

About Progentec Diagnostics, Inc.

Progentec is committed to improving access and health outcomes for patients in therapeutic areas with a high level of unmet need by combining clinically-validated diagnostic interventions with state-of-the-art digital technologies. Through collaborations with research institutions and health practitioners around the world, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.

Forward-Looking Statements:

Statements contained herein that are not historical facts are forward-looking statements that represent management's beliefs and assumptions as of the date of this news release based on currently available information. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements.

Contact:

Mohan Purushothaman

(973) 885-5242

mpurushothaman@progentec.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/precision-medicine-and-diagnostics-expert-hakan-sakul-phd-of-pfizer-joins-the-progentec-board-of-directors-301070191.html

SOURCE Progentec Diagnostics, Inc.

Here is the original post:
Precision Medicine and Diagnostics Expert Hakan Sakul, Ph.D., of Pfizer Joins the Progentec Board of Directors - BioSpace

Read More...

Precision Medicine Market Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020-2026 – 3rd Watch News

June 6th, 2020 8:48 pm

Precision medicine (PM) is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. Personalized nanomedicine involving individualized drug selection and dosage profiling in combination with clinical and molecular biomarkers can ensure the maximal efficacy and safety of the treatment. The major hindrance toward the development of such therapies is the handling of the Big Data, to keep the databases updated. Robust automated data mining tools are being developed to extract information regarding genes, variations, and their association with diseases. Phenotyping, an integral part of PM, is aimed at translating the data generated at cellular and molecular levels into clinically relevant information.Precision Medicine Moves Care from Population-Based Protocols to Truly Individualized Medicine as President of the US announced the Precision Medicine Initiative in his 2015 State of the Union address. Under the initiative, medical care would transition from a one-size-fits-all approach to an individualized approach, in which data on each patients genomic makeup, environment, and lifestyle (the exposome) helps medical professionals tailor treatment and prevention strategies. To achieve the Precision Medicine Initiative mission statement, to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care, researchers and clinicians need vast and varied amounts of data and the technology to ensure that data is widely accessible and usable.

Browse Complete Report with TOC https://univdatos.com/report/precision-medicine-market-current-analysis-and-forecast-2020-2026

Insights Presented in the Report

Based on technology type, the market is fragmented into big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.Recent technological and analytical advances in genomics, have now made it possible to rapidly identify and interpret the genetic variation underlying a single patients disease, thereby providing a window into patient-specific mechanisms that cause or contribute to disease, which could ultimately enable the precise targeting of these mechanisms

Based on the market segment by application type, the market is segmented into oncology, respiratory diseases, central nervous system disorders, immunology, genetic diseases and others. With the advent of precision medicine, cancer treatment is moving from a paradigm in which treatment decision isprimarily based on tumor location and histology followed by molecular information to a new paradigm whereby treatment decisions will be primarily based on molecular information followed by histology and tumor location

Based on the market segment by end-user, the market is fragmented into hospitals & clinics, pharmaceuticals, diagnostic companies, Healthcare-IT firms and others. The precision medicine suppliers that understand technology and the goals of value-based healthcare can create value in the precision medicine value-chain by offering value-based solutions and platforms to interpret and connect data points. There are a number of technology companies who work in the field of precision medicine and more will be founded in the years to come

For better understanding on the market dynamics of Precision Medicine market, detailed analysis was conducted for different countries in the region including North America (United States, Canada, Mexico and Rest of North America), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, Australia, India and Rest of APAC), and Rest of World

Some of the major players operating in the market includeHoffmann-La Roche, Medtronic, Qiagen, Illumina, Abbott Laboratories, GE Healthcare, NanoString Technologies, bioMrieux SA, Danaher Corporation, and AstraZeneca

Request for Sample of the report https://univdatos.com/request_form/form/286

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends and opportunities prevailing in the industry.

Examination of industry attractiveness with the help of Porters Five Forces analysis

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Feel free to contact us for any queries https://univdatos.com/request_form/form/286

Customization Options:

Precision MedicineMarket can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

About us:

UnivDatos Market Insights (UMI), is a passionate market research firm and a subsidiary of Universal Data Solutions. We believe in delivering insights through Market Intelligence Reports, Customized Business Research, and Primary Research. We are a diverse group of some of the most talented people in the research landscape, who with their collective experience, help us drive our machine and creatively solve every business challenge of millennial organizations. Our team comprises of accomplished professionals from leading consulting environments and serve some of the significant Fortune 500 companies around the world.

Contact us:

UnivDatos Market Insights (UMI)

Email: [emailprotected]

Web: https://univdatos.com

Ph: +91 7838604911

Read this article:
Precision Medicine Market Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020-2026 - 3rd Watch News

Read More...

The Disparities In Healthcare For Black Women | EndoFound – Endometriosis Foundation of America – The Blossom

June 6th, 2020 8:48 pm

Like so many people across the United States and around the world, my colleagues and I at Celmatix feel deeply outraged by the brutal and senseless murders of Breonna Taylor, Ahmaud Arbery, and George Floyd. We stand in solidarity with the millions of people lifting their voices in protest and also join countless more in reflecting on what we can do to make this a turning point for racial inequality.

Inequality comes in many forms for People of Color, both here and abroad, but race-related health disparities are among the starkest and most resistant to progress. Being a Black female further amplifies these inequities, which is particularly troubling and ironic given the fact that Women of Color make up the majority of healthcare workers. Over the last few months, the COVID-19 pandemic has brought this unfortunate reality into even more clear focus.

An often-cited quote in the business world is you cant manage what you cant measure. At Celmatix, we have been working for over a decade to address critical gaps in data collection for womens health. This has included thinking outside of the bubble of traditional research metropolises like Boston and San Francisco, and expanding our research partnerships to reproductive health centers of excellence across the US and to biological repositories that allow us to reach women at community health centers and urban hospitals which serve women who may not have access to reproductive specialist care. In addition to investing in diversified data for our scientific and clinical research studies, weve also made significant investments in our Next Gen Womens Project, an ambitious two-year consumer research effort that interviewed or surveyed more than 4K millennial women to understand how their healthcare needs differ from earlier generations of women and to discern their attitudes concerning their reproductive health and fertility. As part of this research, we had the privilege of collaborating withthe Black Womens Health Imperative, Womens Health Magazine, and Oprah Magazineto better understand why Black women are facing higher infertility rates, greater stigma around reproductive challenges, and larger barriers to accessing fertility care.

Taken together, the picture is clear: the disparities we see in womens health funding, research, delivery, innovation, data collection, and outcomes are consistently amplifiedmultifoldfor women of color.As we reflect on policy changes that could have an outsized impact on addressing centuries of racial inequality in the US, we can think of no better place to start than with improving the health of black women.

Black Womens Health ImperativeThe countrys first nonprofit organization created by Black women to help protect and advance the health and wellness of Black women and girls

Black Mamas Matter AllianceThe alliance helps advocate for better legislation to reduce black maternal mortality, highlights necessary areas of research and spreads information about the social determinants of health that influence outcomes like traumatic birth or maternal and infant mortality.

Sister SongSisterSong is a Southern-based, national membership organization; its purpose is to build an effective network of individuals and organizations to improve institutional policies and systems that impact the reproductive lives of marginalized communities

Fertility for Colored GirlsProvides services for underserved Black women and couples. This includes educational programming about treatment options, resources to connect with counselors, financial grants, and monthly support group meetings hosted by seven different chapters across the country,

Linda Villarosa:Journalist

Patrice Peck:Journalist

Laurie Zephyrin, MD:Obgyn, VP Health Care Delivery System Reform at Commonwealth Fund

Reproductive Injustice: Racism, Pregnancy, and Preterm Birth.Davis DA.NY: NYU Press:

Black Lives Matter: Claiming a Space for Evidence-Based Outrage in Obstetrics and Gynecology.Eichelberger KY, Doll K, Ekpo GE, Zerden ML. Am J Public Health. 2016 Oct;106(10):17712. doi: 10.2105/AJPH.2016.303313.

Key Facts on Health and Health Care by Race and Ethnicity,Samantha Artiga and Kendal Orgera. KFF, Published: Nov 12, 2019

When Maternity Wards in Black Neighborhoods Disappear:NYT, Kelly Glass, May 4, 2020

A Preventable Cancer is on the Rise in Alabama:The New Yorker, Eyal Press, March 30, 2020

This article originally appeared on Celmatix, where Dr.Piraye Yurttas Beim, who is also an EndoFound Board Member, is the founder. If you have additional data to share or organizations you would like us to highlight here, please reach out to atinfo@celmatix.comor info@endofound.org. Please also check back as we plan to expand on this list in the coming weeks. And finally, we urge you to help us raise awareness about this important issue by sharing this in your networks.

See the original post here:
The Disparities In Healthcare For Black Women | EndoFound - Endometriosis Foundation of America - The Blossom

Read More...

Digital Genome Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product ; Application ; End User, and Geography – GlobeNewswire

June 6th, 2020 8:48 pm

New York, June 05, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Digital Genome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Application ; End User, and Geography" - https://www.reportlinker.com/p05908643/?utm_source=GNW However, dearth of skilled professionals is likely to restraint the growth of the market during the forecast years.

Digital genome is a complete digital set of genetic material that present in an organism or a cell.Digital genome technology deals with genes and their functions to find the causes behind the chronic diseases and also to fix them.

The technology is associated with the advancements that help to make healthcare more personal and more effective for the treatment.Digital genome facilitates instant access to trait sequences to resolve unending custom queries.

Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, accounting for US$ 4 billion in at least 14 countries. These national genomic medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implement and gather evidence for broader adoption.

The UK has announced the worlds largest genome project as part of 200 million public-private collaboration between charities and pharmaceutical.The UK has already developed the largest genome database in the world through the 100,000 Genomes Project.

Led by Innovate UK as part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases efficiently. Moreover, in August 2018, Boston, a Massachusetts-based company, announced that it landed US$ 4.3 million in seed funding and that it would be partnering with Veritas Genetics, a genome sequencing company. The funds will support the companys mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.

Cardiovascular diseases (CVDs) such as atherosclerosis, angina pectoris, and acute myocardial infarction are a significant cause for mortality in the world owing to the present day hectic lifestyle. As per the data provided by WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and can increase the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As there is a significant increase in diabetes cases across the world, it results in life-changing complications among the population. According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which is expected to reach 62 million in 2045. As chronic diseases are increasing at a faster pace, the research on genomics for life-threatening illnesses has progressed rapidly over the last five years, thereby driving the market growth during the forecast period.

Based on product, the digital genome market is segmented into DNA/RNA analysis, sequencing chips, sequencing and analyzer instruments, sample prep instruments, and sequencing and analysis software. The sequencing and analyzer instruments segment held the largest share of the market in 2019; whereas, the sequencing chips segment is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the digital genome market is segmented into diagnostics, agricultural, academic research, drug discovery, personalized medicine, and other applications. The diagnostics segment held the largest share of the market in 2019; however, personalized medicine segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the global digital genome market is segmented into diagnostics and forensic labs, academic research institutes, hospitals, and others. The diagnostics and forensic labs segment held the highest share of the market in 2019; whereas, the academic research institutes segment is estimated to register the highest CAGR in the market during the forecast period.

The World Health Organization (WHO), Food and Drug Administration (FDA), NHS (National Health Service), and Centers for Disease Control and Prevention are some of the major primary and secondary sources referred for preparing this report.Read the full report: https://www.reportlinker.com/p05908643/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the article here:
Digital Genome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Application ; End User, and Geography - GlobeNewswire

Read More...

Summit Physical Therapy Offers Personalized Treatment To Patients – Patch.com

June 6th, 2020 8:48 pm

This Patch article is sponsored by Summit Physical Therapy Inc.

Summit Physical Therapy, founded in 1988, is an independent, physical therapist-owned, private practice with a convenient location serving Union, Essex and Morris counties. In a world of medicine dictated by corporations, Summit Physical Therapy stays true to its roots with treatment provided only by licensed physical therapists.

In this environment, it is able to provide the personalized treatment that every patient deserves, as well as develop relationships that last longer than treatment. From exercising to stretching, the practice teaches you exactly how to manage your condition so you can live a happy and pain-free life.

John V. Scioscia, president of Summit Physical Therapy, let Patch in on the secrets to his 30-plus years of success in the business, as well as how the practice is providing virtual treatment throughout the COVID-19 pandemic.

Patch: How long have you been doing business in town?

Scioscia: Summit Physical Therapy has been operating since 1988. My wife and I have lived in Summit now for the past 35 years. We raised our children here and have stuck around even after they left. The whole family has been very involved in the community, between sports, my involvement in various boards and organizations, and my wife previously working at Lincoln-Hubbard Elementary School.

Patch: What attracted you to the line of work you're in, and how did you get started?

Scioscia: I have always had a passion for science and fixing things. As a child, this led me in the direction of medicine. I eventually wound up being recruited to Boston University for wrestling with the intention to become a physician. Over the course of my athletic career at Boston, I became involved with physical therapy and athletic training. After college, I started my career in professional sports, but I soon realized I wanted a life that allowed for more time at home with my family. I founded Summit Physical Therapy, and the rest has been amazing.

Patch: If you had to sum up your business mission in five words to a stranger, what would those words be?

Scioscia: Honest. Independent. Experienced. Skilled. Community.

Patch: What's the most satisfying part of your job?

Scioscia: In general, the most satisfying part of my job is helping people. There are some instances when a patient is dealing with a more difficult or complex case and confides that we have made a breakthrough. That is a special moment. As a physical therapist, I get a lot of time to truly invest in a patient's well-being. Making that personal connection and building trust with someone who needs it most is particularly satisfying.

Patch: How would you say your business or organization distinguishes itself from the others?

Scioscia: The physical therapy industry as a whole has changed in recent years. Most have adopted a "team" model, where your care is delivered by numerous aides, technicians and assistants, putting the therapist in more of a supervisory role. At Summit Physical Therapy, your care is delivered entirely by physical therapists. We pride ourselves in being involved in every part of the rehab process. We even take care of sanitizing surfaces ourselves. Nothing is outsourced. Neighbors caring for neighbors. We have also maintained the same staff. Aside from bringing on a new therapist two years ago, our entire staff has worked here for over 20 years. It is hard to say that about any company, let alone a PT clinic. You definitely know someone who has been treated by our therapists.

Patch: What's the best piece of advice you've ever been given when it comes to success?

Scioscia: "You are either moving forward or moving backward." This has applied to how we manage the business but is also applicable to our patients and athletes.

Patch: Are there any new projects or endeavors you're working on that you're extra excited about?

Scioscia: Interestingly enough, we had been planning to start offering telehealth services starting the summer of 2020 prior to this COVID-19 outbreak. Our goals were to provide an easier way for patients to receive care when they could only make it to the clinic on a less-than-optimal basis, provide PT for our patients who travel for business or vacation, provide a more-efficient method to monitor patients as they phase back into normal life after rehab, and to provide athletic program monitoring from a far with our Performance Therapy service.

Obviously, this pandemic moved our rollout date up by a few months, and we have now been practicing telehealth for over three months! Maintaining our theme of honesty, telehealth is not adequate to replace all in-clinic treatment, but is phenomenal for many treatments. We have seen great success with getting patients in for isolated treatments, if in acute or recent-onset pain, progressing to telehealth when symptoms are less irritable. For patients who are in lesser levels of pain, telehealth can be a great option even to start. We are currently offering free telehealth consultations to answer any questions and to help you find what treatment option is best for you.

Patch: Do you have any events coming up in your community?

Scioscia: In November 2019, we started hosting a lecture series at our clinic as well at a few local businesses. Since March, we have converted the series to webinars, which is not only awesome to maintain social distance but allows many more people to access the information from their home. Keep an eye on our Facebook and Instagram for the next webinar we host.

Patch: How can Patch readers learn more about your work and business?

Scioscia: Our website was designed less as a marketing tool and more as a source of information for our patients and the public. We have information on specific conditions, what to expect with PT page, therapist bios, and even a request for an appointment function. We are also on Facebook and Instagram.

Phone: 908-598-9009Email: physicaltherapysummit@gmail.com

More:
Summit Physical Therapy Offers Personalized Treatment To Patients - Patch.com

Read More...

In Vitro Fertilization Market Industry Insights, Trends and Forecast up size 2026 – Cole of Duty

June 6th, 2020 8:48 pm

Market Scenario

Global in Vitro Fertilization market is expected to reach USD 847.8 Bn by 2026 at a CAGR of 10.5 % during the forecast period.

The Global in Vitro Fertilization market is segmented based on product, type of cycle, end-user, and region.

Request for Report Sample: https://www.trendsmarketresearch.com/report/sample/10296

By Product type Reagents, Equipment.By Type of Cycle Fresh Non-Donor IVF Cycles, Frozen Non-Donor IVF Cycles, Frozen Donor IVF Cycles, Fresh Donor IVF Cycles, By End User Hospitals & Research Laboratories, Cryobanks. By region North America & South America, Europe, Asia-Pacific and, Middle East & Africa

In vitro fertilization is a procedure in which egg from women ovary are removed and after that, the egg is fertilized with a sperm in a laboratory procedure, and then the fertilized egg is transferred into the women uterus. In vitro fertilization is used in the management of female infertility.

Major Market Drivers:

Rising rate of infertility Increasing in delayed pregnancies and raising awareness of personalized medicine. Surge in IVF success rate Unfavourable Reimbursement Scenario. Rise in disposable income worldwide.Restraint: High cost of treatment which is restraining this market. Less awareness level for IVF in developing countries which is another restraint of this market.

Request for Report Discount: https://www.trendsmarketresearch.com/report/discount/10296

Global In Vitro Fertilization Market

Strategic Developments in the Global In Vitro Fertilization Market:

In July 2018, Merck launched new products QBOX IVF. This product useful in data transfer between lab instrument and electronic medical record provider. It provides support healthcare professionals in fertility.

In February 2016, Adelaide biotech company, a reproductive health science company expanded IVF expertise into other DNA testing area by the launch of new product. This screening kits count the number of chromosomes in embryo to transfer in an IVFcycle.

Product Insights:Reagents and electrodes segment are expected to reveal exponential CAGR throughout the forecast period due to innovative product launches, and surge in IVF success rate unfavorable reimbursement scenario and rise in disposable income worldwide across the globe.

The North American region is playing the principal role in the global in vitro fertilization market due to the presence of several leading players. Though, Asia-Pacific will be the second major market in the proximate future. The presence of innovative medical advanced technology, a rising rate of infertility, increasing in delayed pregnancies and rising awareness on personalized medicine in the region.Scope of the Global In Vitro Fertilization Market Report

Global In Vitro Fertilization Market, by Product

Reagents EquipmentGlobal In Vitro Fertilization Market, by Type of Cycle

Fresh Non-donor IVF Cycles Fresh donor IVF cyclesGlobal In Vitro Fertilization Market, by End Users

Hospitals & Research Laboratories Cryobanks OthersGlobal In Vitro Fertilization Market, by Instrument

Incubators Cryosystem Cabinet Ovum Aspiration Pump Sperm Aspiration Pump Micromanipulator OthersGlobal In Vitro Fertilization Market, by Technology

Intra-cytoplasmic Sperm Injection (ICSI) Preimplantation Genetic Diagnosis (PGD)Global In Vitro Fertilization Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaGlobal In Vitro Fertilization Market Key Players

Groupe Clinique Ambroise Par amedes MVZ Cologne GmbH AMP Center St Roch, AVA International Clinic Scanfert Bangkok IVF center Betamedics Biofertility Center Bloom Healthcare Bourn Hall Fertility Center Cardone & Associates Reproductive Medicine & Infertility Cook Medical Inc. Coopersurgical Inc. Hamilton Thorne, Inc. Irvine Scientific Laboratoire CCD Merck KGaA Nidacon International AB Nikon Corporation Thermo Fisher Scientific Inc. Vitrolife AB

Full View of Report Description: https://www.trendsmarketresearch.com/report/analysis/MMR/global-in-vitro-fertilization-market

View original post here:
In Vitro Fertilization Market Industry Insights, Trends and Forecast up size 2026 - Cole of Duty

Read More...

The COVID-19 crisis has brought together the scientific community like never before – BSA bureau

June 6th, 2020 8:48 pm

BioSpectrum Asia spoke to Francis Van Parys, Vice-President Commercial, Asia-Pacific, Cytiva (Formerly GE Life Sciences), Seoul, South Korea

The UK headquartered Cytiva is a $3.3 billion global life sciences leader with nearly 7000 associates operating in 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Cytiva announced the collaboration with Takara Bio to develop DNA vaccine to confront the virus in Japan, on May 21. BioSpectrum Asia spoke to Francis Van Parys, Vice-President Commercial, Asia-Pacific, Cytiva (Formerly GE Life Sciences), Seoul, South Korea, who is responsible for providing transformational technologies in biopharmaceutical research, manufacturing and diagnostics to Cytiva customers and partners in the life sciences industry in China, India, Japan, Korea, ASEAN and Australia & New Zealand, for his major plans in store and his plans to enhance growth within the APAC region for the company.

Edited excerpts-

What are the major plans in store for Cytiva? Any new segments to be explored?

Cytiva offers the same high-quality services as we did when we were part of GE Healthcare Life Sciences. It shouldnt be overlooked that we are already a life sciences global leader and we expect our significant growth of recent years to continue. We have been at the forefront of innovation and development of areas such as protein purification, single-use technology and cell and gene therapies.

Cytiva will benefit from being a newly-created organization that is already a global life sciences leader. We have market leading brands such as KTA, Amersham, HyClone and Whatman, among others. We also have more than 100,000 systems in use globally. We will continue innovating from within and working with our customers to develop next generation solutions.

One area where we want to and must do better is sustainability. This is a challenge and opportunity for any organization operating today and one that Cytiva takes very seriously. We dont want to be just compliant in sustainability terms, we want to lead the industry. We will be focusing on areas such as GHG emission, use of plastics, packaging, water management and societal impact among other areas.

How do you plan to enhance your growth within the APAC region?

Asias Economies are seeing rapid growth in past decades meanwhile it suffers for the increases in cardiac disease, cancer and diabetes are subsequently anticipated, driven by increased life expectancy and lifestyle changes. Biotherapeutics are, and will remain, in the forefront of curing many of these diseases and improving the quality of lives across Asia.

Cytiva is well positioned to support the growth in protein-based therapeutics and future treatments, such as cell and gene therapies. Additionally, as the global healthcare system rapidly moves toward more personalized medicine, Cytiva will work with our customers to ensure we are developing the right tools and technologies to ensure efficient manufacturing of novel therapeutics.

How is Cytiva contributing to this fight against COVID-19?

The COVID-19 crisis has brought together the scientific community like never before. Our global team is helping to accelerate the work of researchers, developers, and manufacturers of diagnostics and vaccines, to bring access to much-needed solutions for COVID-19.

In Asia, we just announced the collaboration with Takara Bio to develop DNA vaccine to confront the virus in Japan, on May 21. Genedrive: PCR assay to detect SARS-CoV-2; Sona Nanotech: rapid response lateral flow test; Avacta: Affimer-based point-of-care rapid screening test and University of Queensland: vaccine

What will be the impact of this pandemic on the global economy? How is Cytiva preparing itself?

Cytivas number one priority is the health and safety of our employees and our customers. We are working closely with local governments, and world health authorities to actively monitor the outbreak and take all necessary precautions. We are prepared to walk alongside our customers to help ensure continuity of business, stay connected virtually for support, and provide solutions in this time of need.

The pandemic should not derail us from our key mission, which is to support the worlds development of new technologies and the manufacturing of existing drugs, which are so much important to the diabetes patient, or the cancer patient, or the young child that needs a vaccine. To achieve this mission, you have to shuffle, because suddenly you have to prioritize particular initiatives that you didn't have in mind at all two months ago. We have a task force with special focus on the COVID-19 coronavirus, like we did when Ebola and SARS were global pandemics. This allows us to rapidly respond to the needs of our customers.

Cytiva has comprehensive crisis management andsecurity of supplyprograms in place. We are committed to fulfilling customer orders and regularly adjust our manufacturing output to respond to market demands, while ensuring our operations and service capabilities continue safely. We are also in regular contact with our suppliers regarding their business continuity plans to help minimize disruption of the flow of materials into our manufacturing facilities.

Ankit Kankar

ankit.kankar@mmactiv.com

Follow this link:
The COVID-19 crisis has brought together the scientific community like never before - BSA bureau

Read More...

Targeted Biomarker Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 – Cole of Duty

June 6th, 2020 8:48 pm

QY Research has published a new report on the global Targeted Biomarker market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, The analysts have clarified every part of the market exhaustive fastidious research and full focus to each point. This report gives additional information on statistical data to assist readers with understanding the entire market. This report offers a clear understanding of the present as well as future scenario of the global Targeted Biomarker industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Targeted Biomarker production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Targeted Biomarker market include _ bioMerieux, IntegraGen, Myriad Genetics, Protagen, Qiagen, PerkinElmer, Merck Millipore, Bio-Rad Laboratories, Enzo Biochem, EKF Diagnostics, Meso Scale Diagnostics, LLC. Targeted Biomarker Breakdown Data by Type

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1456215/global-targeted-biomarker-market

Segmental Analysis

The report has classified the global Targeted Biomarker industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Targeted Biomarker manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Targeted Biomarker industry.

Global Targeted Biomarker Market Segment By Type:

, Safety biomarker, Efficacy biomarker, Validation biomarker Targeted Biomarker Breakdown Data by Application,

Global Targeted Biomarker Market Segment By Application:

Diagnostics development, Drug discovery & development, Personalized medicine, Disease risk assessment, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Targeted Biomarker industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Targeted Biomarker market include _ bioMerieux, IntegraGen, Myriad Genetics, Protagen, Qiagen, PerkinElmer, Merck Millipore, Bio-Rad Laboratories, Enzo Biochem, EKF Diagnostics, Meso Scale Diagnostics, LLC. Targeted Biomarker Breakdown Data by Type

Key questions answered in the report:

For Discount, COVID-19 Impact, Customization in the Report: https://www.qyresearch.com/customize-request/form/1456215/global-targeted-biomarker-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Targeted Biomarker Revenue1.4 Market Analysis by Type1.4.1 Global Targeted Biomarker Market Size Growth Rate by Type: 2020 VS 20261.4.2 Safety biomarker1.4.3 Efficacy biomarker1.4.4 Validation biomarker1.5 Market by Application1.5.1 Global Targeted Biomarker Market Share by Application: 2020 VS 20261.5.2 Diagnostics development1.5.3 Drug discovery & development1.5.4 Personalized medicine1.5.5 Disease risk assessment1.5.6 Others 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions2.1 Targeted Biomarker Market Perspective (2015-2026)2.2 Targeted Biomarker Growth Trends by Regions2.2.1 Targeted Biomarker Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Targeted Biomarker Historic Market Share by Regions (2015-2020)2.2.3 Targeted Biomarker Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Targeted Biomarker Market Growth Strategy2.3.6 Primary Interviews with Key Targeted Biomarker Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Targeted Biomarker Players by Market Size3.1.1 Global Top Targeted Biomarker Players by Revenue (2015-2020)3.1.2 Global Targeted Biomarker Revenue Market Share by Players (2015-2020)3.1.3 Global Targeted Biomarker Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Targeted Biomarker Market Concentration Ratio3.2.1 Global Targeted Biomarker Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Targeted Biomarker Revenue in 20193.3 Targeted Biomarker Key Players Head office and Area Served3.4 Key Players Targeted Biomarker Product Solution and Service3.5 Date of Enter into Targeted Biomarker Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Targeted Biomarker Historic Market Size by Type (2015-2020)4.2 Global Targeted Biomarker Forecasted Market Size by Type (2021-2026) 5 Targeted Biomarker Breakdown Data by Application (2015-2026)5.1 Global Targeted Biomarker Market Size by Application (2015-2020)5.2 Global Targeted Biomarker Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Targeted Biomarker Market Size (2015-2020)6.2 Targeted Biomarker Key Players in North America (2019-2020)6.3 North America Targeted Biomarker Market Size by Type (2015-2020)6.4 North America Targeted Biomarker Market Size by Application (2015-2020) 7 Europe7.1 Europe Targeted Biomarker Market Size (2015-2020)7.2 Targeted Biomarker Key Players in Europe (2019-2020)7.3 Europe Targeted Biomarker Market Size by Type (2015-2020)7.4 Europe Targeted Biomarker Market Size by Application (2015-2020) 8 China8.1 China Targeted Biomarker Market Size (2015-2020)8.2 Targeted Biomarker Key Players in China (2019-2020)8.3 China Targeted Biomarker Market Size by Type (2015-2020)8.4 China Targeted Biomarker Market Size by Application (2015-2020) 9 Japan9.1 Japan Targeted Biomarker Market Size (2015-2020)9.2 Targeted Biomarker Key Players in Japan (2019-2020)9.3 Japan Targeted Biomarker Market Size by Type (2015-2020)9.4 Japan Targeted Biomarker Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Targeted Biomarker Market Size (2015-2020)10.2 Targeted Biomarker Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Targeted Biomarker Market Size by Type (2015-2020)10.4 Southeast Asia Targeted Biomarker Market Size by Application (2015-2020) 11 India11.1 India Targeted Biomarker Market Size (2015-2020)11.2 Targeted Biomarker Key Players in India (2019-2020)11.3 India Targeted Biomarker Market Size by Type (2015-2020)11.4 India Targeted Biomarker Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Targeted Biomarker Market Size (2015-2020)12.2 Targeted Biomarker Key Players in Central & South America (2019-2020)12.3 Central & South America Targeted Biomarker Market Size by Type (2015-2020)12.4 Central & South America Targeted Biomarker Market Size by Application (2015-2020) 13Key Players Profiles13.1 bioMerieux13.1.1 bioMerieux Company Details13.1.2 bioMerieux Business Overview and Its Total Revenue13.1.3 bioMerieux Targeted Biomarker Introduction13.1.4 bioMerieux Revenue in Targeted Biomarker Business (2015-2020))13.1.5 bioMerieux Recent Development13.2 IntegraGen13.2.1 IntegraGen Company Details13.2.2 IntegraGen Business Overview and Its Total Revenue13.2.3 IntegraGen Targeted Biomarker Introduction13.2.4 IntegraGen Revenue in Targeted Biomarker Business (2015-2020)13.2.5 IntegraGen Recent Development13.3 Myriad Genetics13.3.1 Myriad Genetics Company Details13.3.2 Myriad Genetics Business Overview and Its Total Revenue13.3.3 Myriad Genetics Targeted Biomarker Introduction13.3.4 Myriad Genetics Revenue in Targeted Biomarker Business (2015-2020)13.3.5 Myriad Genetics Recent Development13.4 Protagen13.4.1 Protagen Company Details13.4.2 Protagen Business Overview and Its Total Revenue13.4.3 Protagen Targeted Biomarker Introduction13.4.4 Protagen Revenue in Targeted Biomarker Business (2015-2020)13.4.5 Protagen Recent Development13.5 Qiagen13.5.1 Qiagen Company Details13.5.2 Qiagen Business Overview and Its Total Revenue13.5.3 Qiagen Targeted Biomarker Introduction13.5.4 Qiagen Revenue in Targeted Biomarker Business (2015-2020)13.5.5 Qiagen Recent Development13.6 PerkinElmer13.6.1 PerkinElmer Company Details13.6.2 PerkinElmer Business Overview and Its Total Revenue13.6.3 PerkinElmer Targeted Biomarker Introduction13.6.4 PerkinElmer Revenue in Targeted Biomarker Business (2015-2020)13.6.5 PerkinElmer Recent Development13.7 Merck Millipore13.7.1 Merck Millipore Company Details13.7.2 Merck Millipore Business Overview and Its Total Revenue13.7.3 Merck Millipore Targeted Biomarker Introduction13.7.4 Merck Millipore Revenue in Targeted Biomarker Business (2015-2020)13.7.5 Merck Millipore Recent Development13.8 Bio-Rad Laboratories13.8.1 Bio-Rad Laboratories Company Details13.8.2 Bio-Rad Laboratories Business Overview and Its Total Revenue13.8.3 Bio-Rad Laboratories Targeted Biomarker Introduction13.8.4 Bio-Rad Laboratories Revenue in Targeted Biomarker Business (2015-2020)13.8.5 Bio-Rad Laboratories Recent Development13.9 Enzo Biochem13.9.1 Enzo Biochem Company Details13.9.2 Enzo Biochem Business Overview and Its Total Revenue13.9.3 Enzo Biochem Targeted Biomarker Introduction13.9.4 Enzo Biochem Revenue in Targeted Biomarker Business (2015-2020)13.9.5 Enzo Biochem Recent Development13.10 EKF Diagnostics13.10.1 EKF Diagnostics Company Details13.10.2 EKF Diagnostics Business Overview and Its Total Revenue13.10.3 EKF Diagnostics Targeted Biomarker Introduction13.10.4 EKF Diagnostics Revenue in Targeted Biomarker Business (2015-2020)13.10.5 EKF Diagnostics Recent Development13.11 Meso Scale Diagnostics, LLC.10.11.1 Meso Scale Diagnostics, LLC. Company Details10.11.2 Meso Scale Diagnostics, LLC. Business Overview and Its Total Revenue10.11.3 Meso Scale Diagnostics, LLC. Targeted Biomarker Introduction10.11.4 Meso Scale Diagnostics, LLC. Revenue in Targeted Biomarker Business (2015-2020)10.11.5 Meso Scale Diagnostics, LLC. Recent Development 14Analysts Viewpoints/Conclusions 15Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See original here:
Targeted Biomarker Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 - Cole of Duty

Read More...

The more COVID-19 vaccines, the merrier – The Japan Times

June 6th, 2020 7:48 am

New York The way the COVID-19 crisis ends is with vaccines not a vaccine. More than one horse can win this race. Some of us might end up getting a shot of a more traditional vaccine, which uses parts of an inactivated virus to stimulate immunity. Others might get vaccines based on emerging technologies that use synthetic versions of the viruss genetic code.

One such novel candidate, based on RNA the single-stranded cousin of DNA and made by Moderna, showed promising results in early human trials, though critics warned the evidence is preliminary. Meanwhile, a different prototype based on DNA made headlines for an experiment that showed it worked in monkeys.

In the end, some vaccines might be extremely effective but harder to scale; others the opposite. Even a less-effective vaccine might work well enough to provide herd immunity in a wider population. Other vaccines might be more appropriate for health care workers, who have to risk exposure on the job, and need protection as soon as possible.

Scientists have created more than 70 vaccine candidates so far. If we end up with two, three, or four vaccines, thats good, since we have seven billion people, says Harvard vaccine researcher Dan Barouch, who led the development of one of the vaccines featured in recent news. His group began working on a vaccine in January, after the virus started spreading in China.

There are good reasons for him and other scientists to be optimistic.

For COVID-19, its clear most humans who get infected recover that alone shows the human immune system can eliminate the virus, he says. That makes it a much easier target than HIV, which he calls unprecedented in the history of vaccinology for its ability to evade the immune system. And the SARS-Cov2 virus doesnt have the fast mutation rate that makes flu viruses a moving target.

Art Krieg, a physician and founder of Checkmate Pharmaceuticals, says hes very optimistic that because the human immune system can successfully battle the virus, so will one or more of the many experimental vaccines.

All vaccines have to provide a danger signal to prime the immune system into acting against an invader. In 1995, Krieg reported the discovery one of these danger signals called CpG DNA which has been used in several vaccines, including one for hepatitis B, and is in some of the experimental candidates fighting against the virus that causes COVID-19.

Next, the vaccine has to mimic the invader in order to get the immune system to create specific antibodies that target the intended enemy. Vaccine designers using genetic material (DNA or RNA) have to stimulate the immune system enough to generate those antibodies, but not so much that the immune system destroys the vaccine before it can complete its mission.

The biggest driver of recent headlines (and stock market drama) was a vaccine produced by the Massachusetts-based company Moderna, which is based on synthetic genetic material identical to parts of the code carried by the coronavirus. The genetic material is RNA. (Other RNA vaccines are being studied by BionTech, Translate Bio, and Curevac.) The RNA tricks human cells into making proteins identical to the spike proteins the virus uses to penetrate human cells. And that, in turn, stimulates the immune system to make antibodies that will be ready to block that protein if the real coronavirus invades.

The excitement about Modernas vaccine followed the release of data from a trial that involved 45 volunteers, though the company only described results for eight of them. Of the eight, all produced antibodies with the desired neutralizing property needed to attack the virus in the future. What happened to the other 37 people? Since this vaccine requires two doses, they probably just didnt have that data yet, says Krieg.

A similar concept is behind DNA vaccines. The one developed by Harvards Barouch made the news for a successful experiment in monkeys. Other DNA vaccines are already in early human trials, including candidates developed by Oxford University, Johnson & Johnson and the Chinese company CanSino Biologics.

These DNA vaccines use synthetic strings of code for making the spike protein carried by the virus. In some of these, the synthetic DNA is injected alone, while in others, it rides into human cells inside a deactivated cold virus (called an adenovirus). The human cells transcribe the DNA to RNA, and then into the decoy spike protein used to create immunity to the real thing. While the prototype developed by Barouchs group at Harvard can be given in two shots, the Oxford DNA vaccine and several others that use cold viruses confer immunity with just one shot, says Krieg.

DNA and RNA arent our only options. Yet another vaccine concept, made by Dynavax, uses the spike protein itself and stimulates the immune system using a synthetic DNA danger signal the CpG DNA. These protein-based vaccines would have to be produced in bulk in fermentation vats, which Krieg says is something the biotech industry is equipped to do.

Krieg says all the novel vaccines work through the same well-established scientific principles, and are very likely to be safe. Still, he says, its well known that vaccines dont work as well in the elderly and immunocompromised. Imperfect vaccines could still eradicate the virus through herd immunity but only if the bulk of the population gets vaccinated. Once the technical hurdles are overcome, there will be social hurdles already, there are movements among anti-vaxxers to resist but its not too soon to plan to surmount them.

Barouch says the ordinarily competitive nature of science has changed, as everyone understands how much is at stake in terms of lives and economic damage. In retrospect, critics might be able to criticize approaches that didnt work, but right now, we need all the ideas we can get.

Science writer Faye Flam is a Bloomberg Opinion columnist.

See original here:
The more COVID-19 vaccines, the merrier - The Japan Times

Read More...

University research sparks clinical trial to test antidepressant that could treat COVID-19 – University of Virginia The Cavalier Daily

June 6th, 2020 7:48 am

Last year, University neuroscientists Alban Gaultier and Dorian Rosen found that antidepressant drug Fluvoxamine may help control inflammation in the immune response system. In May, that discovery sparked a clinical trial at Washington University in St. Louis to determine if the drug could help treat COVID-19 patients, as reducing inflammation in the body has become a key way to fight the virus.

Fluvoxamine, also known as Luvox, is most commonly used to treat Obsessive Compulsive Disorder. The drug functions as a selective serotonin reuptake inhibitor by increasing levels of serotonin a chemical in the brain associated with feelings of well-being and happiness in the body. Since 1983, Fluvoxamine has been used by more than ten million patients around the world.

SSRIs are commonly prescribed because of their safety and tolerability, and many SSRIs, including Fluvoxamine, have been used to treat a variety of other conditions such as migraine headaches, fibromyalgia and anxiety.

In their initial experiment, Gaultier and Rosen determined that the drug reduced the production of cytokines small proteins secreted by the immune system that regulate immunity and inflammation. The drug also proved effective in reducing damage in the inflammatory response during sepsis a life threatening complication of infection in which the immune system spirals out of control and protected mice from lethal shock.

New research has found that many seriously ill coronavirus patients have a large number of cytokines in their blood. These high levels of cytokines likely result from cytokine storms, a severe immune response that releases a large number of cytokines in reaction to a disease or infection. During a cytokine storm, the body begins to attack its own cells rather than use all its resources to fight off the virus.

The information we have so far suggests that the second phase of the illness can involve a life-threatening inflammatory reaction what we call a cytokine storm, said Caline Mattar, assistant professor of medicine in the Washington University infectious diseases division, in a press release from Washington University. We want to learn whether fluvoxamine might help prevent that second phase of the illness.

The trial is being led by Mattar and Washington University psychology professor Eric J. Lenze. It is expected to test whether or not fluvoxamine can prevent cytokine storms in patients with COVID-19, which could help keep the immune system in check and help fight the virus without destroying organs, according to Gaultier.

For some patients, blocking the production of cytokine may be life saving, as the cytokine storms accelerate the breakdown of the immune system, which often results in hospitalization. High fevers, lung damage and respiratory distress symptoms currently experienced by thousands of COVID-19 patients are signs of overworked immune systems.

The trial will test Fluvoxamine in 152 patients with COVID-19 in Illinois and Missouri, as the team's physicians are only licensed to treat people in those states. The patients will either receive the drug or a placebo while quarantined at home. The hope is to target patients who are not sick enough to go to the hospital and hopefully prevent them from getting sicker and being hospitalized. The patients will administer the medication themselves, as the study has been designed to be contactless, and then will use thermometers, fingertip oxygen sensors and automatic blood pressure monitors to monitor their own condition.

Washington Universitys website offers information about who is eligible and how the trial will specifically interact with its patients virtually.

While it may sound unusual to administer a drug typically used to treat OCD as a COVID-19 treatment, Lenze believes it is in line with other alternative treatments being tested at the moment.

Using a psychiatric drug to treat COVID-19 may sound counterintuitive, but its no more counterintuitive than using a malaria drug, Lenze said in the press release.

Similar to Fluvoxamine, the malaria drugsremdesivir and hydroxychloroquine are being tested in off-label ways as COVID-19 treatments. Off-label testing of drugs by health care officials is not uncommon once a drug has been approved by the Food and Drug Administration.

Fluvoxamine received approval in 1994 when the FDA agreed that the benefits of the drug would outweigh its possible side effects like headache and nausea.

Gauliter notes the benefits that come from fluvoxamine already being FDA-approved.

The clinical trial is a smart move to push forward, and since the drug is already approved, it will be easier for people to access it, Gaultier said to The Cavalier Daily.

Even if the drug proves ineffective in fighting COVID-19, patients in the trial will still benefit from the supervision of the doctors and professional recommendations for further treatment.

Gaultier who works closely with the Washington University team believes the clinical trial is set to have its results by the end of June and hopes that fluvoxamine will improve COVID-19 outcomes.

Hopefully the clinical trial will have a positive outcome, which everybody needs, Gaultier said.

Read the original here:
University research sparks clinical trial to test antidepressant that could treat COVID-19 - University of Virginia The Cavalier Daily

Read More...

Do you fall into the ‘at-risk’ category of COVID-19? Here are your rights before returning to work – ABC10.com KXTV

June 6th, 2020 7:47 am

You're 65 and older, considered "at-risk" for getting COVID-19, and you want to go back to work. But your employer is asking you to stay home. What do you do?

SACRAMENTO COUNTY, Calif. As the world takes steps to re-open, those who fall under the most "at-risk" category of contracting the coronavirus may be facing a dilemma.

Multiple ABC10 viewers have reached out, saying they're aged 65+ and that while they're healthy and willing to return to work in person, their employers are telling them to stay at home.

But not allowing employees who are 65 and older, which the Centers for Disease Control and Prevention deem more at risk of COVID-19, could actually be considered age discrimination.

"[Governor Gavin Newsom] came out and said, 'Listen, if you're 65-plus you should really stay at home.' I get that. It makes perfect sense and it's something that we're trying to protect the most vulnerable," said Employment Lawyer Jennifer Shaw. "The problem is from an employment law perspective, if you tell a 65-plus employee that says, 'I'm ready to work. I'm healthy. I'm fine.' That they cannot come to work because they're too old... that's called age discrimination."

As businesses and workplaces begin to reopen, Shaw said employers are facing a "catch-22" by trying to avoid liability and ensure safety by standing by federal and state enforcement like the Occupational Safety and Health Administration and their regulations ensuring employers are providing the safest possible work environment.

Yet, these employers are also trying to avoid liability from age discrimination and not allowing employees of certain ages to return to the workplace.

That's why she's encouraging employees who are experiencing age discrimination to push back by having open conversations with their employers as returning to work should be considered on a case by case basis, rather than just "check the box, you're 65+, you're not coming back."

"Sometimes the employer doesn't have the information they need so I think employees should push back," Shaw said. "If somebody is 65-plus and they want to go back to work, they should tell their employer, 'I'm fine. I'm healthy. I appreciate you looking out for me but I really want to go back to work.' Most employers hopefully are going to get that message."

But on the flip side, some employees who have compromised immune systems and also fall under the most "at-risk" category of coronavirus do not want to go back to work.

"You've got to listen to that as well as an employer," Shaw said.

That's the reality for Kyla Aquino Irving. She has had two kidney transplants, one from her mother and father, and has to take immunosuppressive medication.

This medicine protects her body from attacking her kidney as a "foreign object" but in order to do that dramatically decreases her immune system making her more susceptible to getting sick.

Contracting COVID-19 could keep her in the hospital for an incredibly long time, or could even be potentially deadly. That's why she has to take extra precautions in staying healthy and isn't comfortable returning to her workplace at United Way quite yet.

"In regards to returning to work, I dont really feel comfortable without making sure theres parameters in place, like policies in our office to wash your hands, keep social distance, wear a mask," said Irving.

Luckily, Irving said United Way is extremely understanding and gracious in keeping her safe. While she will continue to work from home, she knows others with compromised immune systems may not be able to do so.

That's why she urges them to visit the Job Accommodation Network.

"It has a great website that allows you to look up any condition, you can even put in compromised immune system and it'll show what the legal limits are for federal law and give you some guidance points for how you can tell your employer what different accommodations you could use or need to make work for you," said Irving.

While others also share the fear of returning to work, Shaw reiterates that you do need the approval of a physician to truly deem you unsafe from working in an office our work space outside the home.

Just saying Im afraid to go back to work is not enough," said Shaw. "But the employer cant make the person come back to work.

Shaw said options for employees not comfortable returning to a workplace are to file for unemployment. However, employees do not have a legal entitlement to remain off of work unless they are caring for someone who is ill related to COVID-19. This falls under new leave laws created by California during the pandemic, but leave laws aren't anything new.

"There are people who are pregnant who have a right to stay home. There are people who are taking care of a child who is ill that have a right to stay home," Shaw said. "So these new leave laws that we have had to sort of get used to because of COVID19, those layer on the other leave that other people already had and are entitled to. So the employer really has to have a brush when theyre looking at the right does this person have an entitlement to not come back to work?"

As for if you're taking care of someone with a compromised immune system, but are healthy yourself, Shaw said if a physician or healthcare provider to the individual with the compromised immune system would like the caregiver to self-isolate in order to not expose the individual with the compromised immune system, they may be entitled to time off related to COVID-19.

As for Shaw's overall message, it's one of ensuring health and safety during this time to both employees and employers.

"I really want people to think about what is best for their health. I also want employers to think about whats best for their employees," said Shaw. "Everyone is struggling, supporting the community and we do have to have a little grace we maybe have to go a little farther than we have in the past in order to try and help and accommodate and make it work."

Follow the conversation onFacebook with Andie Judson.

FOR THE LATEST CORONAVIRUS NEWS, DOWNLOAD OUR APP:

Stay In the Know! Sign up now for theDaily Blend Newsletter

Continue reading here:
Do you fall into the 'at-risk' category of COVID-19? Here are your rights before returning to work - ABC10.com KXTV

Read More...

Cannabis and Immunity: What Science Says About Cannabinoids and Immune Systems – HealthMJ

June 6th, 2020 7:47 am

Could weed boost your immunity? Its possible. Some science suggests THC and CBD positively impact immunity.

Some claim that cannabis calms a cytokine storm, for example, preventing your immune system from overreacting against itself. Some even believe that cannabis is more effective than traditional drugs, or that its an effective medication for various illnesses.

Theres a lot of information (and misinformation) about cannabinoids and immunity. Today, were exploring what science says about cannabis and your immune system. Extensive research has already been put into cannabis and nutritional supplements, but given the gravity of the COVID-19 coronavirus health threat there is a necessary need to cover marijuana's THC and hemp's CBD and the whole cannabis plant's medicinal and therapeutic effects towards the body immune system's immunity.

While this cannabis use-related immune system guide is organized differently than the best CBD oils, drinks, gummies, and skincare rankings, there is much to be said, sorted and shown as marijuana and hemp make their way back into consumers medicine cabinets as a natural remedy and reemerging alternative. It's time to review what science says about cannabinoids and our immune system's function and whether or not cannabis can be a real immunity booster that individuals turn to based on medical research and scientific literature.

You could write a textbook on how the immune system works. Well provide a short version.

First, your immune system recognizes a foreign invader in your body. Your immune system detects a flu virus in your bloodstream, for example, and realizes it needs to take action.

In response to the foreign invader, your immune system sends white blood cells to the area to engulf the target. These white blood cells (also known as leukocytes) are the key to your immune system. Good white blood cells help your body fight foreign invaders.

There are other factors for immune response, including proteins called cytokines and lymphocytes. These compounds target specific types of invaders. White blood cells called phagocytes, for example, target invading organisms, while neutrophils help fight bacteria. These and other compounds work together to help your body fight off foreign invaders.

During this immune response, your body creates antibodies. Lymphocytes respond to the foreign invader by creating antibodies.

Antibodies can recognize foreign invaders and target them, but they cant fully destroy them without help. Thats why they join with T cells also known as killer cells to remove invaders from the body.

Some believe that cannabis boosts immunity by supporting different aspects of your immune system. Cannabis may actually help your immune system by suppressing it, preventing your immune system from overreacting against your body.

Cannabis contains natural chemicals called cannabinoids. Two of the best known cannabinoids include THC and CBD. These and other chemicals could help your body fight invaders, supporting your immune system in different ways.

The chemicals in cannabis target your endocannabinoid system, which includes CB1 receptors (mostly found in the brain) and CB2 receptors (mostly found in your peripheral nervous system or immune cells).

Science suggests theres a relationship between the endocannabinoid system and the immune system. But does that mean cannabis supports immunity? The answer is complicated.

The endocannabinoid system consists of two types of receptors, including:

CB1 Receptors: Mostly located in the brain.

CB2 Receptors: Mostly located in the peripheral nervous system or immune cells.

Immune cells have approximately 10 to 100 times more gene expression of CB2 compared to CB1. When endocannabinoids activate these receptors, they may control various immune system functions including cell signaling cascades and homeostasis of your immune system.

Science shows that endocannabinoids have a particularly noticeable effect on the lymph nodes and the gut, which have strong concentrations of immune cells.

Immune cells can even create their own cannabinoids. Yes, your body produces its own endogenous cannabinoids.

Immune cells create endogenous cannabinoids like 2-AG, which regulates your immune system.

These cannabinoids work differently from exogenous cannabinoids like THC and CBD, which come from outside the body.

Science suggests THC and CBD have immunosuppressive effects. That means they inhibit cell signaling that normally leads to pro-inflammatory immune system responses, also known as active immune responses.

Suppressing the immune system may seem like a bad thing but not necessarily. In many cases, its in your bodys best interest to suppress its immune system.

Weve established that exogenous cannabinoids (like THC and CBD) seem to suppress the immune system, changing your bodys immune response. Thats not necessarily a bad thing.

Chronic diseases like inflammatory bowel disease (IBD) and psoriasis occur when the immune system is overactive. Your immune system is dysregulated, and your immune responses are heightened. This creates inflammation and pain.

If you have chronic inflammation, then it could be linked to an overactive or ineffective immune system. Your body recognizes the foreign invader, and your body knows it needs to kill that foreign invader, but the compounds your body is sending to that foreign invader are not working to remove it from your body.

Over time, this ineffective immune response leads to inflammation and pain. For many, this inflammation and pain doesnt go away. Its chronic.

Thats why some suggest that THC and CBD can help. They reduce your bodys immune response, preventing it from overreacting against invaders. THC and CBD could relieve pain and discomfort caused by immune dysfunction.

CBD is prized for its ability to reduce inflammation. Science agrees, and CBD has shown some evidence of reducing inflammation when applied topically.

Inflammation sounds like a bad word, but its simply your bodys immune response. Your body sends white blood cells and other compounds to a location on your body, and this produces inflammation.

Toxins can also increase body inflammation, and inflammation seems to be a biomarker of disease. Inflammation may increase your risk of disease or illness, and many common diseases seem linked to inflammation.

This 2016 study showed that CBD applied transdermally (through your skin) significantly reduced arthritis by reducing certain cells related to the inflammatory immune response.

Researchers concluded that topical CBD application has therapeutic potential for relief of arthritis pain-related behaviors and inflammation without evidence side-effects, praising CBD gel for reducing joint swelling, improving limb posture scores, and boosting other metrics of arthritis.

CBD is prized for its ability to reduce arthritis pain, but increasing research shows other compounds in cannabis may have similar effects. Some cannabinoids suppress cytokines, for example, which appear to play a crucial role in inflammation.

Cytokines are a class of small proteins that play a crucial role in your immune system. Your body secretes cytokines, then sends cytokines to the source of infection.

That all sounds good but cytokine activity isnt always good in a problematic immune system. If your immune system is dysfunctional, then cytokines can do more harm than good.

The Spanish Flu of 1919 was unique because it killed young, healthy people with strong immune systems. Researchers found that the influenza virus triggered a cytokine storm: it forces the immune system to overreact, sending too many cytokines to the source of the infection. These cells got confused and attacked everything including crucial body functions. People with the strongest immune systems died in hours because of this cytokine storm.

Theres some evidence that COVID-19 reacts in a similar way. Some COVID-19 fatalities are linked to an overreacting immune system.

Tumor-necrosis-factor alpha (TNF-) is one type of cytokine. Overexpression of TNF- is linked with diseases like IBD and Crohns Disease. Theres also some evidence that TNF- is linked with cancers, anxiety, and depression.

We already know CBD can help with pain and inflammation related to IBD. However, certain studies have also found that CBD can lower TNF- levels in mice. This suggests that CBD could manage your bodys cytokine response, although more research is necessary.

Interleukins are another common type of cytokine. Interleukins affect your bodys immune response. Research shows interleukins are impacted by endogenous cannabinoids (produced by your body) and exogenous cannabinoids (like CBD and THC taken orally).

Some research suggests that cannabis affects interleukins, changing the way these cytokines respond. Other research, however, shows mixed results.

This 2019 study found that CBD alone did not inhibit a specific type of interleukin (IL-8), although a full spectrum version of cannabis sativa did inhibit IL-8.

Based on these results, its possible theres an entourage effect, with other cannabinoids also impacting your bodys immune response. CBD may not work on its own, but CBD combined with the other hundreds of chemicals in the cannabis plant could play a role in immune response.

As reported by Hanna Webster at Ganjapreneur, cannabis seems to target other immune system proteins, including one called NF-B. This protein is involved in immune regulation. It lays dormant in unstimulated cells, then is activated by signals coming from outside the cell.

NF-B is in charge of cell proliferation, cell survival responses, and other immune system responses. When NF-B is activated, it causes an immune response. Inhibiting this pathway can decrease chronic inflammation from excessive cell signaling.

Studies have found that cannabis sativa extract and CBD alone could impact the immune system. This 2019 study, for example, found that both cannabis sativa extract and CBD alone inhibited the NF-B pathway, mostly through TNF-, which can activate the NF-B pathway. These compounds also affected genes associated with skin inflammation, which could make the compounds valuable for conditions like psoriasis or rheumatoid arthritis.

That study also revealed another complication of the immune system: all elements of your immune system seem interconnected. When cannabis impacts one aspect of your immune system like one type of cytokine it can also indirectly impact many other parts of your immune response.

When cells die, its called apoptosis. THC has been linked to apoptosis in multiple cell types.

Cell death may sound bad but it can actually be a good thing. Apoptosis is a natural body function. It clears away damaged cells, forcing your body to make new ones. New, healthy cells may be more effective. Older, damaged cells may be more prone to disease.

Studies have shown that CBD causes apoptosis in a variety of cell types. Scientists believe this effect is linked with the activation of CB2 receptors. When CB2 receptors are blocked, it prevents natural apoptosis. By activating CB2 receptors, cannabis may facilitate your bodys natural cell death process.

THC has been used to treat tumor suppression in cancer patients, and some researchers believe this is linked to cell death. By facilitating your bodys natural cell death processes, THC could help your body fight cancer and other invaders.

Dont get too excited about these anti-cancer benefits: researchers have found that certain cells, including breast cancer cells, are not impacted by cannabinoid-induced apoptosis. More research needs to be done to understand this connection.

Could cannabis treat or prevent the COVID-19 coronavirus? Theres no evidence supporting that claim.

In fact, evidence suggests that cannabis has immuno-suppressive effects, which means it weakens the immune system. This can be helpful for certain conditions say, if you have an overactive immune system. For conditions like the cold or flu virus, however, a weakened immune system is not a good thing.

Cannabis may suppress your immune system, inhibiting certain cytokines. Cytokines are the proteins that help your immune system do its job. By inhibiting these cytokines, cannabis could make your body more susceptible to cold or flu symptoms.

Despite the lack of evidence, you can find plenty of anecdotal evidence online proclaiming that CBD has antiviral applications and that it can reduce the risk of coronavirus, among other benefits.

Some argue that suppressing the immune system prevents the infamous cytokine storm, for example, where your immune system overreacts to the virus. Theres some evidence that COVID-19 fatalities are linked to an overreacting immune system, although this effect was more prominent in the 1919 Spanish Flu than in the COVID-19 coronavirus.

Overall, theres no scientific evidence analyzing how cannabis reacts to COVID-19 or the coronavirus. However, theres some evidence showing that CBD could treat viral infections.

Theres some small evidence that CBD has antiviral benefits. Because of these small studies, some suggest using CBD to treat the COVID-19 coronavirus. Lets take a closer look at this connection.

Researchers recently published an in vitro study showing that CBD had a direct antiviral effect against the Hepatitis C virus. Researchers inserted CBD into a test tube with the Hep C virus, then found it killed the virus.

In another study, researchers found that CBD reduced neuro-inflammation (inflammation in the brain) in a virus-induced animal model of multiple sclerosis. However, researchers believed these effects werent technically antiviral: instead, they were linked to the anti-inflammatory properties of CBD.

You can also find anecdotal evidence online of people using CBD to treat viral infections, including herpes and shingles.

A group of British and Italian researchers acknowledged these anecdotal reports in this study, where they concluded that evidence was plausible on the basis of the anti-inflammatory and analgesic properties of CBD. However, researchers did not suggest CBD had an intrinsic antiviral effect.

Researchers in Israel are studying whether CBD could treat graft-versus-host disease (GVHD), a potentially fatal condition with a mortality rate over 80%.

GVHD occurs when your immune system rejects an organ or bone marrow transplant. Your immune system recognizes the transplant as a foreign invader, then attacks the transplant, triggering a deadly chain reaction in the body.

Results are encouraging so far: researchers have found that CBD could suppress the bodys immune response to GVHD, which could increase the chances of a successful organ or bone marrow transplant.

Both COVID-19 fatalities and GVHD are triggered by extreme immune overresponses. However, GVHD is not triggered by a virus. Its possible CBD could suppress the immune system to prevent GVHD but have no impact on COVID-19.

What does all of this research mean about your cannabis usage and immunity?

First, it appears cannabinoids are immuno-suppressive. They suppress the immune system. Natural cannabis chemicals like THC and CBD significantly reduced cytokine expression.

Because cannabis suppresses the immune system, it could support some conditions but not others.

Weakening the immune system could help control your bodys response to inflammation and pain, for example, which could be caused by an overactive immune system. In some conditions, your immune system does more harm than good. Its overreacting, and that mean its less effective.

Suppressing the immune system isnt always a good thing, however.

Cannabis could have negative effects on conditions like HIV, for example, or any other condition where the patient has a weakened immune system. Cannabis may also be problematic for conditions where cells are not affected by cannabinoid-induced apoptosis (like the breast cancer cells mentioned above).

Theres some evidence that cannabinoids reduce inflammation. We know that CBD seems to reduce inflammation when applied trans-dermally, for example.

Theres also evidence that cannabinoids have a transient effect on the immune system, which means they help treat acute or chronic inflammation without affecting the immune systems long-term ability to defend itself. In other words, it could give your immune system a boost when needed without impairing its ability to do its job.

Overall, ordinary cannabis usage should not weaken your immune system on its own. However, if you are already sick, its possible that excessive cannabis usage could make the condition worse. Suppressing your immune system can reduce your bodys ability to fight the flu or cold virus, for example.

As more research gets released, were learning more about how cannabis affects the immune system in both positive and negative ways.

Read more:
Cannabis and Immunity: What Science Says About Cannabinoids and Immune Systems - HealthMJ

Read More...

India coronavirus dispatch: The human bodys immune response to the virus – Business Standard

June 6th, 2020 7:47 am

Here is a round-up of articles from Indian news publications on how the country is dealing with the Covid-19 pandemic. From Indias first recession that is not driven by agri sectors, to missing-in-action Parliament, and why a study suggests blood cancer patients usually survive Covid read these and more in todays India dispatch.

Expert Speak

This will be Indias first recession driven by non-agri sectors: Indias economy is now set to lose 10 per cent of its gross domestic product (GDP), thanks to the after-effects of Covid-19. Eight states in India contribute to more than 50 per cent of its GDP. Within these eight states, almost 42 per cent of the state GDP is driven by areas that are now considered red zones. How is it going to play out, and what is Indias overall economic prospect looking? Read this interview with D K Joshi, chief economist of the rating agency CRISIL. Read more

Opinion

Indias Parliament is missing in action: In ordinary times, Parliament would have its next session in the second half of July. In todays extraordinary circumstances, Parliament should meet sooner, perhaps within a couple of weeks. India prides itself in being the worlds largest democracy as well as the information technology provider to the world. It is imperative that Parliament harnesses the countrys IT strengths to buttress our credentials as a performing democracy. Read more here

Long Reads

Covid-19, population, and pollution a road map for the future: The impact of this pandemic is likely to be multidimensional, creating a health crisis in the first instance with spillover effects including hunger crisis, deepening of poverty, recession, and disequilibrium in the supply chain. There are two other aspects that are important for the long run, and that this pandemic has brought to our attention: pollution and population (density). Read more here

Indias poor may have lost Rs 4 trillion in the coronavirus lockdown: To avoid a livelihood crisis of severe magnitude in India, programmes by central and state governments should try to rebuild workers lost incomes through assistance in the form of cash or kind as well as through public works programmes. There is scope for launching a massive public works programme across the country which will address the problem of stagnant demand as well as of supply-side constraints. Read more here

Managing Covid-19

From treatment to medical gear, patients paying more in Covid times: The central government and courts have stepped in to regulate some prices but not others. For example, the Supreme Court set a cap of Rs 4,500 on RT-PCR testing, the Delhi High Court mandated that antibody kits be sold to the Indian Council for Medical Research at Rs 400 and the government capped the prices of hand sanitisers and surgical masks.

But several vital items were left out of price regulation; these include N95 masks, personal protective equipment (PPE), face shields, goggles, the charges for being admitted into intensive care and the overall treatment charges. Read more here

In Mumbai, Covid-19 patients are dying as they wait for ambulances and hospital beds: In public hospitals, coronavirus patients have been asked to share beds, sleep on the floor, or share wards with corpses that have been left on beds for hours because families refuse to claim them. People calling the corporations Covid-19 helpline are often told there are no beds available. The situation is no better with ambulances the states 108 helpline runs barely 100 ambulances in the city, private ambulance services are expensive and insufficient, and patients are left high and dry when they need help the most. Read more here

Karnataka increases quarantine time to 3 weeks for Maharashtra returnees: The Karnataka government has tweaked quarantine requirements for people arriving from Maharashtra, raising the isolation time from a fortnight to three weeks, an official said on Wednesday. The 21-day quarantine regimen is for all asymptomatic people returning from Maharashtra, considering most of the Covid-19 cases reported in Karnataka are having domestic travel history to that state. Read more here

Factories open in Noida, but where are the workers? After the lockdown, the government has given permission to reopen factories and industries to boost Indias economy. But, where are the factory workers? Ironically, during the third phase of lockdown, several industries were allowed to open but at the same time, the government also started special Shramik trains that saw migrant workers leave en masse. Read more here

Understanding Covid-19

If otherwise fit, blood cancer patients usually survive Covid: People with blood cancer are expected to be at higher risk of Covid-19 infection due to a weakened immune system from the cancer and the treatment they receive. Clinical researchers from Queen Mary University of London (QMUL) and Barts Health NHS Trust have now studied the outcome of Covid-19 infection in patients with blood cancer. The study found that even if patients were actively having intensive treatment for blood cancer that weakened their immune system, they usually recovered from Covid-19 as long as they were otherwise fit and well. Read more here

The human bodys immune response to the novel coronavirus: Understanding the bodys response to the SARS-CoV-2 virus is important to comprehend the underlying mechanisms of vaccines and antiviral drugs. Coronaviruses have not popped up all of a sudden. We have been living with various human and animal coronaviruses for decades. Nevertheless, this novel coronavirus is wreaking havoc owing to its rapid rate of transmission. Further investigation will unravel the complete behavioural patterns of this virus, allowing researchers to develop a potential vaccine soon. Read more here

More:
India coronavirus dispatch: The human bodys immune response to the virus - Business Standard

Read More...

How Have Your Habits Changed In the Midst of This Pandemic? – k99.com

June 6th, 2020 7:47 am

Maybe it's more home-cooked meals or more cleaning days in your household.

Our worlds were rocked by this pandemic. And by "worlds", I mean our collective world and our own individual worlds. It's been a rough few months and I pray that we are able to get past this quickly and get some normalcy back.

However, we may have picked up some new habits during this down time.

I'm a believer that you can establish both good and bad habits in a matter of 30 days if done with consistency. For most of the nation, our lockdown was double that time. So what habits have you formed or what kind of behavior changes have you seen since the shutdown in March?

A recent Harris Poll, done for the University of Phoenix, reveals that we are living our lives differently than we did before the pandemic hit.

One major, and obvious, change is our cleaning regimen. 70 percent of respondents say that they are scrubbing down the house more. And speaking of changes within the house, 61 percent of us are cooking at home more and 50 percent are stocking the kitchen and pantry for emergency situations.

We've also become a little more thoughtful. 29 percent of poll takers say they have stopped making impulsive decisions. I believe this is because when you act impulsively, there is usually money being spent. Since we're all pinching our pennies a little more, I'm thinking we're exercising more caution. For me, this means I'm visiting Target less often since I can't control myself in that store.

How have things changed in your household or for just you as an individual?

Excerpt from:
How Have Your Habits Changed In the Midst of This Pandemic? - k99.com

Read More...

Drug used to treat cancer might help reduce COVID-19 severity in patients: Study – Outlook India

June 6th, 2020 7:47 am

Washington, Jun 6 (PTI) Scientists have observed that a drug which is already approved to treat several blood cancers, is associated with reduced respiratory distress and a reduction in the overactive immune response in COVID-19 patients, an advance that may lead to a potential therapeutic for novel coronavirus infection.

According to the researchers, including those from the National Cancer Institute in the US, the cancer drug acalabrutinib blocked the protein Bruton tyrosine kinase (BTK) in COVID-19 patients, and provided clinical benefit to a small group of them.

The study, published in the journal Science Immunology, noted that the findings should not be considered clinical advice, and remain to be tested in a randomised, controlled clinical trial.

The BTK protein, according to the scientists, plays an important role in the immune system, including in macrophages which are immune cells that can cause inflammation by producing proteins known as cytokines.

These proteins, the researchers said, act as chemical messengers that help to stimulate and direct the immune response.

In some patients with severe COVID-19, the study said a large amount of cytokines are released in the body all at once, causing the immune system to damage the function of organs such as the lungs -- a process known as a "cytokine storm."

The current study involved 19 patients with a confirmed COVID-19 diagnosis that required hospitalisation, as well as with low blood-oxygen levels and evidence of inflammation.

According to the scientists, 11 of the 19 patients had been receiving supplemental oxygen for a median of two days, and eight others had been on ventilators for a median of 1.5 days.

The study noted that within one to three days after they began receiving the cancer drug, majority of patients in the supplemental oxygen group experienced a substantial drop in inflammation, and their breathing improved.

It said eight of the 11 patients were able to come off supplemental oxygen, and were discharged from the hospital.

Although the benefit of acalabrutinib was reported to be less dramatic in patients on ventilators, the scientists said four of the eight patients were able to come off the ventilator, two of whom were eventually discharged.

According to the scientists, the ventilator patient group was extremely clinically diverse and included patients who had been on a ventilator for prolonged periods of time and had major organ dysfunction.

Two of the patients in this group died, they said.

An analysis of blood samples from the patients revealed that the levels of interleukin-6 (IL-6), a major cytokine associated with hyperinflammation in severe COVID-19, decreased after treatment with acalabrutinib.

The scientists said counts of lymphocytes, an immune cell type associated with worse outcome in COVID-19 patients, also rapidly improved in most patients.

When the researchers tested blood cells from patients with severe COVID-19, who were not in the study, and compared it with samples from healthy volunteers, they found that the patients with severe COVID-19 had higher activity of the BTK protein and greater production of IL-6.

Based on these findings, they suggested that acalabrutinib may have been effective since its target, BTK, is hyperactive in severe COVID-19 immune cells.

However, in a note of caution, the scientists also mentioned in the study that the most common adverse events associated with long-term acalabrutinib therapy included "low-grade headache, diarrhea, pyrexia and upper respiratory tract infections."

They said the safety profile of acalabrutinib in patients with severe COVID-19 needs to be confirmed in a prospective clinical trial.

"Further correlative studies will be needed to understand the basis for response or resistance to BTK inhibition in patients with such advanced disease," the scientists wrote in the study. PTI VISVIS

Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: PTI

Excerpt from:
Drug used to treat cancer might help reduce COVID-19 severity in patients: Study - Outlook India

Read More...

TTU School of Veterinary Medicine receives $1.4 Million CPRIT recruitment grant – KLBK | KAMC | EverythingLubbock.com

June 6th, 2020 7:46 am

by: News Release & Posted By Staff | newsweb@everythinglubbock.com

Artist rendering of the Texas Tech University School of Veterinary Medicine in Amarillo.(Photo provided by Texas Tech University)

LUBBOCK, Texas (NEWS RELEASE) The following is a news release from Texas Tech University:

TheCancer Prevention and Research Institute of Texas(CPRIT) has awarded a transformative grant to theTexas Tech University School of Veterinary Medicine in Amarillodesigned to bring to the schools growing faculty one of the worlds leading cellular and molecular biologists.

The $1.4 million grant will allow Klementina Fon Tacer, a postdoctoral researcher at St. Jude Childrens Research Hospital in Memphis, Tennessee, since 2016, to join the veterinary school faculty. Supported by this award, Fon Tracer will investigate the novel mechanisms that protect mammalian germ cells against stress and how those mechanisms are co-opted in cancer, with the ultimate goal of advancing cancer treatment and fertility preservation of childhood cancer survivors.

The hope is Fon Tacers research will establish a strong foundation for a comparative oncology research center in the School of Veterinary Medicine.

What we do and why we do it is simple. We are here to benefit Texas and Texans, saidGuy Loneragan, dean of the School of Veterinary Medicine. Dr. Fon Tacer is going to change lives for generations to come. When we first had the chance to meet her, it was clear. Her research is transformative and will impact countless Texans in the years ahead. I am so thankful to the CPRIT Oversight Committee for awarding Texas Tech this recruitment award to make it possible to bring Dr. Fon Tacer to Texas and to the School of Veterinary Medicine. Her work in comparative oncology will save lives.

The Recruitment of First-Time, Tenure-Track Faculty Members Award, one of seven awarded by CPRIT this week and part of 13 academic research recruitment and product development awards totaling $56 million, is the first CPRIT grant awarded to the School of Veterinary Medicine, which is scheduled to open its doors to students for the first time in the fall of 2021.

Fon Tacer earned her Doctor of Veterinary Medicine (DVM) and Doctor of Philosophy in Biochemistry and Molecular Biology from the University of Ljubljana in Slovenia. She also holds a Master of Science in Biochemistry and Molecular Biology from the University of Ljubljana.

Fon Tacer is not new to Texas, having served as a postdoctoral researcher and Fulbright Fellow at the University of Texas Southwestern Medical Center in Dallas from 2006-2008. From there, she returned to the University of Ljubljana as a postdoctoral researcher and later as an adjunct assistant professor on the veterinary faculty at the University of Ljubljana until 2012.

Among her research interests at St. Jude Childrens Research Hospital are melanoma antigen genes (MAGE), very common cancer immunotherapy targets and their role in cancer reproduction, metabolism and stress response.

We are very excited to have support from CPRIT for building the faculty of our new School of Veterinary Medicine, saidJoseph Heppert, vice president of theOffice of Research & Innovation. One-health research themes developed by faculty like Dr. Tacer will have enormous benefits for both human and animal health. TheTexas Tech University Systemhas strong potential for collaboration in one-health research across the Texas Tech andTexas Tech University Health Science Centercampuses, and we are extremely proud to be adding new faculty who will capitalize on these opportunities.

Thanks to the generosity of Amarillo and communities across Texas, and the commitment of legislators from around the state, the Texas Tech University School of Veterinary Medicine in Amarillo, established in 2018, is working to enroll its first class in the fall of 2021, pending approval by the AVMA Council on Education.

The School of Veterinary Medicine will recruit and select students with a passion to practice and succeed in rural and regional communities. Its curriculum is focused on the competencies and skills necessary for success in practices that support these communities. Texas Techs innovative and cost-efficient model partners with the wider community of veterinary practices across the state to provide clinical, real-world experiential learning.

In June 2019,Gov. Greg Abbott signed into law the biennial state budget, which appropriated $17.35 million for the School of Veterinary Medicine in Amarillothat will go toward operational needs in order to get the school up and running. The appropriation included language directing Texas Tech to move forward in establishing the school.

To date, CPRIT has awarded almost $2.5 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs. CPRIT has recruited 181 distinguished researchers, supported the establishment, expansion or relocation of 36 companies to Texas and generated more than $3 billion in additional public and private investment. CPRIT funding has advanced scientific and clinical knowledge and provided 5.7 million life-saving cancer prevention and early detection services, reaching Texans from all 254 counties. In November 2019, voters in Texas approved a constitutional amendment authorizing an additional $3 billion in bonds for cancer research and prevention.

(News release from Texas Tech University)

Continue reading here:
TTU School of Veterinary Medicine receives $1.4 Million CPRIT recruitment grant - KLBK | KAMC | EverythingLubbock.com

Read More...

COVID-19 control efforts appear to be containing swine flu – The Pig Site

June 6th, 2020 7:46 am

The Western College of Veterinary Medicine has completed a summary of seasonal influenza over the past two years.Dr Susan Detmer, an Associate Professor in the Department of Veterinary Pathology with the Western College of Veterinary Medicine, says COVID-19 has presented an interesting scenario.

Speaking to Farmscape, she explains:

"With less movement of people, even between the provinces in Canada, we're actually seeing less disease and less transmission. There's still movements of pigs and we do see viruses move with the movement of pigs. We are seeing that happen, the viruses are on these farms so they're not going to just disappear.

"But we do expect to see less influenza in people so long as they're doing their social distancing, they're not interacting with large groups, they're not travelling on planes. All of that is going to hopefully benefit the pigs this fall.

"We'll see what happens but it is something that some of us are keeping an eye on because, this time of year it's southern hemisphere. Australia, South America, those areas where flu is transmitting still because it's their winter time, what comes back to us come next fall, we'll if that is any different.

"If there's less virus being transmitted in Australia because they're trying to stop the Coronavirus from transmitting as well, then we could actually have a better fall flu season because people are not interacting at the levels that they normally would."

Dr Detmer says all of those steps to reduce the spread of COVID-19, staying home when sick, self isolating, creating bubbles around families, wearing facemasks, are all going to help stop the spread of other respiratory viruses like influenza.

Read more:
COVID-19 control efforts appear to be containing swine flu - The Pig Site

Read More...

Final words on the ‘whitest profession’ – dvm360

June 6th, 2020 7:46 am

Editors note: The following letters are part of an ongoing conversation about diversity and inclusion in veterinary medicine that started when dvm360 published this article late last year. For the beginning of the conversation, the original letters can be found here and here.

I would like to make one final comment and response about recent letters to the editor regarding the whitest profession in America. I believe Dr. McKenzies assertion that the makeup of our profession is predominantly white as a result of systemic racism is incorrect. (More on the whitest profession, April 2020). It is obvious from his website that Dr. McKenzie is a firm believer in evidence-based medicine. In this discussion, the evidence and statistics from the American Association of Veterinary Medical Colleges (AAVMC) do not support his assertion.

According to the AAVMC, the percentage of underrepresented minorities applying to veterinary colleges in 2016 was 21.6%, and the actualenrollment in those same programs was almost identical (21.1%). Im not a statistician, but this leads me to conclude, perhaps naively,that the makeup of the veterinary student population and of our profession as a whole mirrors the racial makeup of the applicant pool. (The same holds true for the percentage of women now enrolled in U.S. and Canadian veterinary programs. Most classes are 80% female, reflecting the 82% of female applicants in the 2016 AAVMC report.)

Despite many initiatives, including by my alma mater, Purdue University, the number of underrepresented minorities applying to veterinary colleges is still way below that of white applicants, and there is no evidence to support that the admissions to veterinary schools are or have been the result of intentional discrimination or systemic racism.

The good news is that the percentage of minorities graduating in 2016 was 15.8%substantially higher than the approximately 4.5% when I graduated from Purdue's DVM program in 1982, with most of the gains being made since the launch ofthe Diversity Matters initiative in 2005.

In 1969, one of my early mentors who allowed me to job shadow was an African-American graduate of Tuskegee University. He was instrumental in my decision to become a veterinarian.During my 38-year career, I have never known (nor can I imagine) a colleague who was unwilling to encourage or mentor elementary, high school or college students of any minority group that showed interest in our profession.

My concern is that using the terminology the whitest profession in America will in fact dissuade underrepresented minorities from seeking to join our profession by insinuating that the deck is stacked against them before they even attempt to shadow a veterinarian or pursue an education that will prepare them for admission to colleges of veterinary medicine. In this regard, I believe words matter.

Likewise, should I be expected to dissuade my white, privileged grandsons from seeking a career in veterinary medicine, as we must now and for the foreseeable future balance the racial makeup of the profession? Shouldsimilar programs developed to attract underrepresented minorities to veterinary medicine be made available to them?

I thank Dr. McKenzie for his feedback. I was very hesitant to get involved in discussions about race, but once again, Imust disagree about using the term whitest profession in America. I believe it does nothing to enhance the promotion of diversity in our profession.

Dr. Paul Clemente

Fort Wayne, Indiana

_______________________________________________________________________________________________

I appreciate Dr. Clementes willingness to engage in a discussion of such a contentious topic, and I acknowledge the difficulty in having substantive conversations about such a complex issue in the letters page of a magazine. However, I feel obliged to point out that his understanding of my comments, and of the role of racism in the demographic makeup of the veterinary profession, is incorrect.

That the proportion of veterinarians from underrepresented groups (at least those that are tracked) is similar to the proportion of applicants from those groups to veterinary colleges suggests that intentional discrimination in admissions is not the reason for the disproportionate predominance of white veterinarians. This is encouraging, both because such a direct manifestation of racism would reflect badly on the profession and because it would be a clear violation of federal law.

This does not demonstrate, however, that systematic racism is not at work or that the poor representation of specific groups is due to a natural or inherent lack of interest among those groups in joining the profession. The composition of the applicant pool reflects a much more insidious and widespread constellation of factors that impede potential applicants from underrepresented communities at a much earlier stage on the path to becoming veterinarians. This includes disparities in educational opportunities and resources as well as a paucity of mentors and role models in the profession to encourage children in minority communities to consider veterinary medicine as a career. This lack of representation in our profession, not the acknowledgment of it in the phrase whitest profession in America, is one of the barriers to greater diversity. Sadly, the deck is stacked against people of color, and solving the problem begins with clearly and honestly labeling it.

The suggestion that diversity and inclusion is a zero sum game in which white men must be discriminated against to make room for others is an outdated and disappointingly simplistic characterization of the problem and the available solutions. Dr. Clementes grandsons are indeed privileged that their ethnicity is not an obstacle to their career aspirations, as it still too often is for people of color. They should be encouraged to pursue their ambitions and, with a grandfather who is a veterinarian, they can likely see themselves as part of a profession that looks comfortable and familiar. The grandchildren of people of color should have the same opportunities and encouragement as Dr. Clemente provides his grandsons, and right now they frequently do not. Inclusion means making such encouragement and opportunities available to everyone, not discriminating against one group to favor another.

I would encourage Dr. Clemente, and everyone interested in inclusion and diversity in veterinary medicine, to read Navigating Diversity and Inclusion in Veterinary Medicine, edited by Lisa M. Greenhill and colleagues. This excellent, evidence-based resource traces the roots of the problem and offers strategies for improvement.

Brennen McKenzie, MA, MSc, VMDThe SkeptVet

Read more:
Final words on the 'whitest profession' - dvm360

Read More...

Ohio State researchers testing breathalyzer to detect COVID-19 – The Ohio State University News

June 6th, 2020 7:46 am

One of the most common COVID-19 tests involves a long swab pressed deep into the nasal cavities and while the test can be administered quickly, it has been described as unpleasant and uncomfortable.

Now researchers at The Ohio State University are working on a testing system that would require a simple exhaled breath. Perena Gouma is the primary investigator of a team developing a breathalyzer device that will sample breath for key biomarkers of the infection. She says it would serve as an alternative to current tests that are expensive, can take a long time to get results and require specialized personnel to do the sampling and to analyze the results.

Gouma, director of the Advanced Ceramics Research Laboratory and professor in the College of Engineering, is working with co-investigator Andrew Bowman, associate professor of veterinary preventive medicine. The project was awarded a nearly $200,000 National Science Foundation EAGER grant this month under a program supporting exploratory, early-stage research on untested, but potentially transformative, ideas or approaches.

Breath analysis is not really a technique that is used widely in the medical field yet, so it is considered early-stage work, Gouma said. [We] have a sensor device that detects nitric oxide and VOCs (volatile organic compounds) in breath and can be used to tell you about the onset of an infectious disease.

In addition to nitric oxide, the device examines two other metabolites that could specifically indicate the presence of a COVID-19 infection even in asymptomatic patients. Exhaling once in the breathalyzer may help with earlier detection of the onset of the disease, as well as with monitoring of the severity of the infection, which could help reduce the risk for worsening of the symptoms and allow timely therapeutic intervention, she said.

The new project builds upon Goumas invention of a hand-held breathmonitor that may provide early detection of flu before symptoms appearprior to her arrival at Ohio State. The COVID-19 breathalyzer involves advances on nanomaterials for detecting specific breath gases at the concentrations of interest for making a diagnosis.

The breathalyzer gives results rapidly (15 seconds response time), it is extremely inexpensive, and it is easy to use so that there is no need for trained personnel to perform the test, Gouma said. The results can be viewed directly on the display or they can be transferred to the physician wirelessly.

We are working on making these hand-held monitors that will be widely distributed and theyre very inexpensive, she said. The technology evolved from the sensors used for monitoring gases in an automotive exhaust thats how we started on breath analysis 20 years ago.

Gouma said the NSF-funded project would not have been possible without the collaboration with the College of Veterinary Medicine, the College of Medicine and the Wexner Medical Center. She said these connections make Ohio State very appealing for interdisciplinary research between engineering and medicine (nanomedicine).

Thats one of the advantages of Ohio State. You dont find many institutions that have the No. 1 vet med school in the world and also a world-class medical school, she said. Its also serendipity because COVID-19 is a zoonosis, a disease that comes from animals, and the vet med school had years of experience studying coronaviruses and the flu in animals.

Furthermore, the Wexner Medical Center has been treating COVID-19 patients from the beginning of the pandemic, so it offers unique insights to this project.

Gouma said the collaboration is critical for engineers developing medical diagnostics for humans and animals who need to consult with colleagues who have expertise in medicine to ensure that the ideas have merit and to validate their claims through clinical trials.

If the device proves to be accurate, portable and effective, it could be used to screen travelers before they step on a flight or to test students and teachers before they head back into the classroom. It would also be used in the Medical Intensive Care Units and in every hospital and doctors office as a bedside test. Gouma said the breathalyzer technology may become the platform to help detect metabolic problems like cancer, Alzheimers disease or diabetes, by choosing the appropriate biomarker

Visit link:
Ohio State researchers testing breathalyzer to detect COVID-19 - The Ohio State University News

Read More...

Does Fido have coronavirus? Tufts researchers are testing hundreds of animals to find out – The Boston Globe

June 6th, 2020 7:46 am

Should people be wary when cats jump into their laps? Is it okay to pet someones dog passing by on the street? Are veterinarians in danger during checkups?

Since March, a team of Tufts researchers has tested hundreds of animals looking for clues on whether they can get the virus and pass it along to humans, or vice versa, in the Coronavirus Epidemiological Research and Surveillance (CoVERS) study.

We know this virus came out of the animal population, so theres some reason to believe this could affect other animals, said Dr. Jonathan Runstadler, professor of infectious diseases and global health at Cummings School of Veterinary Medicine at Tufts. We know there are sporadic reports of transmission from humans to pets.

The risk of the virus spreading in the other direction, from animals to humans, is considered to be low, the US Centers for Disease Control and Prevention says on its website.

A German shepherd from New York became the first dog to test positive for the virus in the country, the US Food and Drug Administration announced Tuesday. Several cats have tested positive since late April.

Out of the nearly 400 animals the Tufts team has sampled, none have tested positive.

Along with common domestic animals, the Tufts team has tested pigs, bats, horses, and exotic animals, according to Runstadler.

The lack of positive tests was expected, Runstadler said, but its no reason for the team to stop the research any time soon.

[The pandemic] is an active outbreak, and with viral outbreaks, things can change, he said.

To test animals, the team uses materials similar to those in a human test kit. The researchers assemble kits themselves, including swabs, media, and molecular reagents.

In the first phase of the study, animal owners who have volunteered get their animals tested at the lab or gather nasal and mouth swabs from their pets at home and submit them.

The best outcome would be that we dont see infections in animals, and that we see that trend continue over time, and that its not a risk, Runstadler said.

The second phase of the study focuses on pets owned by people who have the virus or are at higher risk of having the virus due to contact with someone who was infected. Researchers are looking for the rare circumstances in which a human may have transmitted the virus to an animal, or the even rarer circumstance in which the animal transmits the virus to a human, Runstadler said.

Researchers are particularly interested in these circumstances for future reference, Runstadler said.

When the next pandemic occurs, the Tufts researchers want scientists to have a solid understanding of animal transmission to be better prepared.

We expect that events like this epidemic will happen again, Runstadler said.

The research will end, he said, when the coronavirus pandemic is over.

Matt Berg can be reached at matthew.berg@globe.com. Follow him on Twitter @mattberg33.

See original here:
Does Fido have coronavirus? Tufts researchers are testing hundreds of animals to find out - The Boston Globe

Read More...

Page 537«..1020..536537538539..550560..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick